Sciformix to launch labelling service

Published: 5-Mar-2015
Packaging Regulatory

Includes ready to use technology solutions to support workflow, content and process control


Sciformix, a leading Scientific Process Organisation (SPO), will offer a new labelling platform from the end of this month.

The platform is a fully integrated managed service offering processes and technology that cover the entire labelling process from signal/change triggers to package implementation. It includes performance, quality and compliance metrics and pre-configured, ready-to-use technology solutions to support workflow, content management and process control.

Sciformix says benefits of the new platform include efficiency and scale to accelerate label updates, deployment and implementation.

Manish Soman, President and CEO, Sciformix Corporation, said: 'Sciformix’s long-term strategy focuses on evolving and enhancing our service and technology offerings for our clients, broadening our global reach, and growing and diversifying our customer base. Being able to offer this end-to-end labelling platform supports all of these objectives.'

He added: 'We have formed strategic partnerships with niche labelling solution providers and act as an integrator of technology enablers by leveraging our labelling, regulatory and IT expertise.'

With operations in North America, Europe and Asia, Sciformix offers comprehensive global labelling services, including labelling content development and lifecycle management, operational support and workflow management, regional labelling support, and artwork/package component labelling management.

The new platform will be presented at the Marcus Evans 3rd Annual Labelling Compliance Conference in Boston, MA, US, from 25–26 March.

  • Companies:
  • Sciformix Corporation
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

EudraVigilance: what’s changed?

Read more
In May 2017, the updates to the EudraVigilance system were approved for release and the changes went into effect on 22 November 2017, implemented by the European Medicines Agency (EMA)

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  3. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  4. Tagrisso receives full approval in the EU For patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

EudraVigilance: what’s changed?

In May 2017, the updates to the EudraVigilance system were approved for release and the changes went into effect on 22 November 2017, implemented by the European Medicines Agency (EMA)
Media

Automated and integrated drug safety database solution

Through its collaboration with Oracle Health Sciences, Sciformix is able to offer its customers a fully automated and integrated safety database solution, allowing easy reporting and analytics for improving the quality and efficiency of drug safety operations
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Labelling and generics: who is accountable?

Bindu Narang, Director of Regulatory Affairs and Scientific Writing, Sciformix Corporation, considers the impact of proposed US FDA labelling regulations on the generic drugs sector
Regulatory

Sciformix expands into Europe with new office in Manchester, UK

European office to support growth in client delivery and customer backup
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Outsourcing clinical trial safety data management

Outsourcing clinical trial safety data is a relatively recent trend that requires confidence in the selected partner. Supriya Desai, Director, Medical Safety Operations, and Suhasini Sharma, Director, Medical Affairs, Sciformix Corporation consider what to look for
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

A successful path to fulfilling pharmacovigilance obligations

As the number of innovator pharmaceutical and generic manufacturer partnerships grow, the lines of responsibility for meeting pharmacovigilance requirements can get blurred. Chitra Lele, of Sciformix Corporation, looks at routes to managing the issue
Packaging

How robots enhance the efficiency of pharmaceutical labelling

At ACHEMA 2024 (Hall 4.1, Stand B20), HERMA will demonstrate how robotics make challenging labelling processes more reliable, more cost-efficient and faster
Subscribe now